Construction and validation of prognostic scoring models to risk stratify patients with acquired immune deficiency syndrome-related diffuse large B cell lymphoma

作者全名："Zhao, Han; Liu, Rongqiu; Tao, Yu; Bertero, Luca; Feng, Lizhi; Liu, Bo; Chen, Zhimin; Guan, Jialong; Liao, Baolin; Li, Linghua; He, Haolan; You, Hua"

作者地址："[Zhao, Han; Feng, Lizhi; Liu, Bo; Chen, Zhimin; Guan, Jialong; Liao, Baolin; Li, Linghua; He, Haolan] Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Infect Dis Ctr, Guangzhou 510000, Peoples R China; [Liu, Rongqiu] Guangzhou Med Univ, Dept Oncol, Affiliated Canc Hosp & Inst, Guangzhou, Peoples R China; [You, Hua] Chongqing Med Univ, Natl Clin Res Ctr Child Hlth & Disorders, Key Lab Child Dev & Disorders, China Int Sci & Technol Cooperat Base Child Dev &, Chongqing, Peoples R China; [Bertero, Luca] Univ Turin, Dept Med Sci, Pathol Unit, Turin, Italy; [You, Hua] Chongqing Med Univ, Dept Pediat Hematologyand Oncol, Lab Excellence Insyst Biomed Pediat Oncol, Childrens Hosp, Chongqing 401122, Peoples R China"

通信作者："He, HL (通讯作者)，Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Infect Dis Ctr, Guangzhou 510000, Peoples R China.; You, H (通讯作者)，Chongqing Med Univ, Dept Pediat Hematologyand Oncol, Lab Excellence Insyst Biomed Pediat Oncol, Childrens Hosp, Chongqing 401122, Peoples R China."

来源：JOURNAL OF MEDICAL VIROLOGY

ESI学科分类：MICROBIOLOGY

WOS号：WOS:000996236800038

JCR分区：Q1

影响因子：6.8

年份：2023

卷号：95

期号：5

开始页：　

结束页：　

文献类型：Article

关键词：acquired immune deficiency syndrome; diffuse large B cell lymphoma; human immunodeficiency virus; prognostic model; risk stratification

摘要："Acquired immune deficiency syndrome (AIDS)-related diffuse large B cell lymphoma (AR-DLBCL) is a rare disease with a high risk of mortality. There is no specific prognostic model for patients with AR-DLBCL. A total of 100 patients diagnosed with AR-DLBCL were enrolled in our study. Clinical features and prognostic factors for overall survival (OS) and progression-free survival (PFS) were evaluated by univariate and multivariate analyses. Central nervous system (CNS) involvement, opportunistic infection (OI) at lymphoma diagnosis, and elevated lactate dehydrogenase (LDH) were selected to construct the OS model; CNS involvement, OI at lymphoma diagnosis, elevated LDH, and over four chemotherapy cycles were selected to construct the PFS model. The area under the curve and C-index of GZMU OS and PFS models were 0.786/0.712; 0.829/0.733, respectively. The models we constructed showed better risk stratification than International Prognostic Index (IPI), age-adjusted IPI, and National Comprehensive Cancer Network-IPI. Furthermore, in combined cohort, the Hosmer-Lemeshow test showed that the models were good fits (OS: p = 0.8244; PFS: p = 0.9968) and the decision curve analysis demonstrated a significantly better net benefit. The prognostic efficacy of the proposed models was validated independently and outperformed the currently available prognostic tools. These novel prognostic models will help to tackle a clinically relevant unmet need."

基金机构："National Natural Science Foundation of China [81911530169]; CQMU Program for Youth Innovation in Future Medicine [W0202]; Talent Program of Chongqing Health Commission; Chongqing Science and Technology Bureau [CSTB2022NSCQ-MSX0227, cstc2022jxjl120022]; Municipal and University (Hospital) joint funding project of Guangzhou Municipal Science and Technology Bureau [202201020250, 202201020253, 2023A03J0796]; Medical Key Discipline Program of Guangzhou-Viral Infectious Disease"

基金资助正文："National Natural Science Foundation of China, Grant/Award Number: 81911530169; CQMU Program for Youth Innovation in Future Medicine, Grant/Award Number: W0202; Talent Program of Chongqing Health Commission; Chongqing Science and Technology Bureau, Grant/Award Numbers: CSTB2022NSCQ-MSX0227, cstc2022jxjl120022; Municipal and University (Hospital) joint funding project of Guangzhou Municipal Science and Technology Bureau, Grant/Award Numbers: 202201020250, 202201020253, 2023A03J0796; Medical KeyDiscipline Program of Guangzhou-Viral Infectious Diseases (2021 to 2023)"